Successful Nedaplatin Desensitization Therapy in a Patient with Platinum-sensitive Recurrent Ovarian Cancer: A Case Report and Literature Review

Overview

Journal Gynecol Oncol Rep

Publisher Elsevier

Date 2022 Sep 19

PMID 36118075

Authors

Tetsuya Kokabu

Kohei Aoyama

Yosuke Tarumi

Hisashi Kataoka

Kaori Yoriki

Taisuke Mori

Affiliations

Soon will be listed here.

Abstract

Desensitization protocols of platinum-based agents are recommended for patients with a history of hypersensitivity reaction (HSR). Herein, we report the first case of a successful desensitization therapy with nedaplatin after HSR to carboplatin and nedaplatin for platinum-sensitive recurrent ovarian cancer. A 53 year-old woman was diagnosed with stage IIIC serous carcinoma of the ovary and underwent primary debulking surgery followed by an adjuvant chemotherapy. The tumor relapsed 4 times in 10 years after the initial treatment, and platinum-based chemotherapy was performed on each occasion. HSR to carboplatin without and with desensitization protocol occurred during the 9th cycle of treatment and 2nd cycle of retreatment, respectively. Additionally, HSR to nedaplatin occurred during the 16th cycle of nedaplatin treatment. A four-step desensitization protocol with nedaplatin was conducted without occurrence of any severe adverse event. Nedaplatin desensitization regimen could be a new alternation for HSR to platinum-based agents.

Citing Articles

Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data.

Li K, Yin R Front Immunol. 2024; 15:1346464.

PMID: 38312839 PMC: 10834667. DOI: 10.3389/fimmu.2024.1346464.

Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions.

Zon A, Bednarek I Int J Mol Sci. 2023; 24(8).

PMID: 37108749 PMC: 10146189. DOI: 10.3390/ijms24087585.

References

Patil S, Long A, Ling M, Wilson M, Hesterberg P, Wong J . A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol. 2011; 129(2):443-7. DOI: 10.1016/j.jaci.2011.10.010. View

Rose P, Fusco N, Smrekar M, Mossbruger K, Rodriguez M . Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol. 2003; 89(3):429-33. DOI: 10.1016/s0090-8258(03)00178-1. View

Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T . Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020; 130:114-125. DOI: 10.1016/j.ejca.2020.02.020. View

Confino-Cohen R, Fishman A, Altaras M, Goldberg A . Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005; 104(3):640-3. DOI: 10.1002/cncr.21168. View

Hesterberg P, Banerji A, Oren E, Penson R, Krasner C, Seiden M . Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009; 123(6):1262-7.e1. DOI: 10.1016/j.jaci.2009.02.042. View

Ge L, Li N, Yuan G, Sun Y, Wu L . Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer. Am J Cancer Res. 2018; 8(6):1074-1082. PMC: 6048404. View

Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y . 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol. 2014; 20(3):566-73. DOI: 10.1007/s10147-014-0731-1. View

Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M . Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int J Mol Sci. 2020; 21(11). PMC: 7312982. DOI: 10.3390/ijms21113805. View

Park H, Lee S, Kim S, Lee J, Hong D . Does Carboplatin Rapid Desensitization Change Its Adverse Drug Reactions Other than Hypersensitivity and Efficacy in Patients With Ovarian Cancer?. Allergy Asthma Immunol Res. 2020; 12(6):1046-1059. PMC: 7492508. DOI: 10.4168/aair.2020.12.6.1046. View

10.

Michikami H, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K . Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies. J Obstet Gynaecol Res. 2012; 39(1):330-5. DOI: 10.1111/j.1447-0756.2012.01893.x. View

11.

Vetter M, Khan A, Backes F, Bixel K, Cohn D, Copeland L . Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol. 2018; 152(2):316-321. DOI: 10.1016/j.ygyno.2018.10.037. View

12.

Weingart S, Zhang L, Sweeney M, Hassett M . Chemotherapy medication errors. Lancet Oncol. 2018; 19(4):e191-e199. DOI: 10.1016/S1470-2045(18)30094-9. View

13.

Castells M, Tennant N, Sloane D, Hsu F, Barrett N, Hong D . Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008; 122(3):574-80. DOI: 10.1016/j.jaci.2008.02.044. View

14.

Li Q, Cohn D, Waller A, Backes F, Copeland L, Fowler J . Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. Gynecol Oncol. 2014; 135(1):90-4. DOI: 10.1016/j.ygyno.2014.07.104. View

15.

Cakmak M, Kaya S, Can Bostan O, Ozturk Aktas O, Damadoglu E, Karakaya G . Successful desensitization with chemotherapeutic drugs: a tertiary care center experience. Eur Ann Allergy Clin Immunol. 2021; 54(2):90-94. DOI: 10.23822/EurAnnACI.1764-1489.202. View